CMV Viremia Clinical Trial
Official title:
An Expanded Access Protocol of ATA230 (Third-Party Donor-Derived Cytomegalovirus-Specific T Cells) for the Treatment of CMV Viremia or Disease in Subjects for Whom There Are No Other Comparable Options
NCT number | NCT03010332 |
Other study ID # | ATA230-EAP-201 |
Secondary ID | |
Status | No longer available |
Phase | |
First received | |
Last updated |
Verified date | April 2019 |
Source | Atara Biotherapeutics |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Expanded Access |
This is an expanded access protocol designed to provide access of ATA230 to subjects with cytomegalovirus (CMV) viremia or disease, who are intolerant to, or failed, standard antiviral therapy and have no comparable treatment options.
Status | No longer available |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: A subject will be considered eligible to participate in the study if the following inclusion criteria are satisfied: 1. Has a clinically documented condition associated with CMV disease (eg, interstitial pneumonia, hepatitis, encephalitis, retinitis, colitis) or microbiological evidence of CMV viremia or tissue invasion with CMV infection (as determined by viral culture or levels of CMV DNA in blood or body fluids) 2. The CMV disease or CMV viremia is characterized by at least one of the following: 1. CMV disease is persistent or clinically progressing despite = 2 weeks of antiviral therapy 2. CMV viremia/disease is persistent or increasing (determined by quantitation of blood CMV DNA) despite = 2 weeks of antiviral therapy 3. A genetic mutation associated with antiviral drug resistance is present 4. Unable to continue antiviral drugs due to drug-associated toxicity. 3. No other comparable or satisfactory therapies are available for treatment of CMV 4. Not eligible for any other trials supporting development of ATA230 5. For subjects who received an alloHCT, the underlying disease for which the alloHCT was performed is in morphologic remission 6. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3× the upper limit of normal (ULN) and total bilirubin < 2.5×ULN unless caused by CMV 7. Availability of appropriate ATA230 cell lot (ie, HLA partially-matched and restricted CMV-CTLs) 8. Subject or subject's representative is willing and able to provide written informed consent Exclusion Criteria: A subject will not be eligible to participate in the study if any of the following criteria are met: 1. Receiving concomitant investigational therapy (co-enrollment in a non-interventional study or a study for follow-up or sample collection only is permitted) 2. Need for antimetabolite agents (eg, methotrexate), or extracorporeal photopheresis 3. Antithymocyte globulin or similar anti-T cell antibody therapy = 4 weeks prior to the first dose of ATA230 (on Day 1 of Cycle 1) 4. Need for vasopressor or ventilator support 5. Pregnancy, except when ATA230 is clearly needed 6. Female of childbearing potential or male with a female partner of childbearing potential unwilling to use a highly effective method of contraception 7. Inability to comply with study procedures |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Atara Biotherapeutics |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03443791 -
Cytomegalovirus (CMV) Vaccines: Reinfection and Antigenic Variation
|
N/A | |
Enrolling by invitation |
NCT06263218 -
Real-world CMV Outcomes Among Kidney Transplant Recipients in Brazil
|
||
Recruiting |
NCT05432778 -
Cytomegalovirus Prophylaxis With Letermovir in Heart Transplant Recipients
|
Phase 2 | |
Recruiting |
NCT04320303 -
CMV Infection and Immune Intervention After Transplantation
|
N/A | |
Completed |
NCT01329185 -
Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients
|
Phase 2 | |
Recruiting |
NCT06011486 -
Expansion of Virus-Specific Lymphocytes for Cell Therapy
|
Phase 1 | |
Completed |
NCT04018261 -
Virus-specific Activated T Lymphocytes From a Donor in Hematopoietic Progenitor Transplanted Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT04298502 -
The Molecular Mechanism of CMV-driven NKG2C+NK Cell Expansion in Human
|
||
Recruiting |
NCT03798301 -
Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells
|
Phase 1 |